, , ,, ;;each of T11-13 is independently selected from N, C(R13); where T11-13 are C(R13) or one or two of T11-13 are N, and the rest of T11-13 are C(R13); T14 and T17 are N; each of T15 and T16 are CH; each of E11-12 is independently selected from N(CH3); L1 is a single bond; L2 is selected from a single bond or C(=O)NH; R11 is selected from H or methyl; R12 is selected from H, methyl, F, Cl; R13 is selected from H, methyl, trifluoromethyl, trifluoromethoxy, F, Cl, CN, methylaminocarbonyl, methylsulphonyl, morpholinylsulphonyl, 2-imidazolyl or dimethylamino; Q12 is selected from phenyl; where structural unit; ;and B are selected from structures specified in claim 1. Invention also relates to specific compounds of formula (I).; ;(I).;EFFECT: technical result is obtaining novel heterocyclic compounds, useful as hedgehog pathway inhibitors, especially as SMO inhibitors and accordingly are effective in treating cancer.;14 cl, 22 tbl"/>
QUINOLINE DERIVATIVES AS SMO INHIBITORS
FIELD: chemistry.;SUBSTANCE: invention relates to organic chemistry and specifically to a heterocyclic compound of formula (I) or a pharmaceutically acceptable salt thereof, where A is selected from; , , ,, ;;each of T11-13 is independently selected from N, C(R13); where T11-13 are C(R13) or one or two of T11-13 are N, and the rest of T11-13 are C(R13); T14 and T17 are N; each of T15 and T16 are CH; each of E11-12 is independently selected from N(CH3); L1 is a single bond; L2 is selected from a single bond or C(=O)NH; R11 is selected from H or methyl; R12 is selected from H, methyl, F, Cl; R13 is selected from H, methyl, trifluoromethyl, trifluoromethoxy, F, Cl, CN, methylaminocarbonyl, methylsulphonyl, morpholinylsulphonyl, 2-imidazolyl or dimethylamino; Q12 is selected from phenyl; where structural unit; ;and B are selected from structures specified in claim 1. Invention also relates to specific compounds of formula (I).; ;(I).;EFFECT: technical result is obtaining novel heterocyclic compounds, useful as hedgehog pathway inhibitors, especially as SMO inhibitors and accordingly are effective in treating cancer.;14 cl, 22 tbl
展开▼
机译：杂环化合物或其可药用盐技术领域本发明涉及有机化学，尤其涉及式（I）的杂环化合物或其药学上可接受的盐，其中A选自; ，，<图像文件=” 00000466.JPG“ he =” 22“ imgContent =” undefined“ imgFormat =” JPEG“ wi =” 15“ />，<图像文件= “ 00000467.JPG” he =“ 24” imgContent =“未定义” imgFormat =“ JPEG” wi =“ 16” />，<图像文件=“ 00000468.JPG” he =“ 24” imgContent =“未定义” imgFormat =“ JPEG“ wi =” 21“ /> ;; T 11-13 的每一个都独立地选自N，C（R 13 ）;其中T 11-13 是C（R 13 ）或T 11-13 的一个或两个是N，其余的T < Sub> 11-13 是C（R 13 ）; T 14 和T 17 为N; T 15 和T 16 均为CH; E 11-12 各自独立地选自N（CH 3 ）; L 1 是单键; L 2 选自单键或C（= O）NH; R 11 选自H或甲基; R 12 选自H，甲基，F，Cl; R 13 选自H，甲基，三氟甲基，三氟甲氧基，F，Cl，CN，甲基氨基羰基，甲基磺酰基，吗啉基磺酰基，2-咪唑基或二甲基氨基; Q 12 选自苯基;结构单元; B选自权利要求1中指定的结构。本发明还涉及式（I）的特定化合物。 效果：技术成果是获得新的杂环化合物，可用作刺猬蛋白通路抑制剂，尤其是作为SMO抑制剂，因此可有效治疗癌症。; 14 cl，22 tbl
展开▼
